SRNE
Income statement / Annual
Last year (2022), Sorrento Therapeutics, Inc.'s total revenue was $62.84 M,
an increase of 18.78% from the previous year.
In 2022, Sorrento Therapeutics, Inc.'s net income was -$559.33 M.
See Sorrento Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$62.84 M
|
$52.90 M
|
$39.99 M
|
$31.43 M
|
$21.19 M
|
$151.86 M
|
$8.15 M
|
$4.59 M
|
$3.83 M
|
$460,148.00
|
Cost of Revenue |
$33.45 M |
$13.03 M |
$9.94 M |
$12.24 M |
$10.07 M |
$11.03 M |
$3.70 M |
$1.95 M |
$2.04 M |
$4,440.00 |
Gross Profit |
$29.39 M |
$39.87 M |
$30.05 M |
$19.20 M |
$11.12 M |
$140.83 M |
$4.46 M |
$2.64 M |
$1.78 M |
$455,708.00 |
Gross Profit Ratio |
0.47 |
0.75 |
0.75 |
0.61 |
0.52 |
0.93 |
0.55 |
0.58 |
0.47 |
0.99 |
Research and Development
Expenses |
$221.23 M
|
$206.92 M
|
$111.34 M
|
$106.88 M
|
$76.96 M
|
$55.53 M
|
$42.18 M
|
$31.34 M
|
$23.98 M
|
$9.02 M
|
General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$63.64 M
|
$38.33 M
|
$24.22 M
|
$20.13 M
|
$9.99 M
|
$6.32 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$5.37 M
|
-$2.04 M
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$182.34 M
|
$196.86 M
|
$116.18 M
|
$103.56 M
|
$63.64 M
|
$32.96 M
|
$22.18 M
|
$20.13 M
|
$9.99 M
|
$6.32 M
|
Other Expenses |
$4.33 M |
$4.14 M |
$4.05 M |
$3.94 M |
$3.01 M |
$2.61 M |
$845,000.00 |
$1.16 M |
$2.35 M |
$804,070.00 |
Operating Expenses |
$407.89 M |
$407.92 M |
$231.57 M |
$214.38 M |
$140.60 M |
$88.49 M |
$64.35 M |
$52.63 M |
$36.32 M |
$16.14 M |
Cost And Expenses |
$441.34 M |
$420.95 M |
$241.51 M |
$226.61 M |
$150.67 M |
$99.52 M |
$68.05 M |
$54.58 M |
$38.36 M |
$16.14 M |
Interest Income |
$0.00 |
$0.00 |
$24,000.00 |
$1.09 M |
$921,000.00 |
$241,000.00 |
$272,000.00 |
$24,000.00 |
$12,000.00 |
$9,615.00 |
Interest Expense |
$8.57 M |
$10.22 M |
$20.18 M |
$36.14 M |
$57.63 M |
$4.98 M |
$1.61 M |
$1.65 M |
$1.63 M |
$253,194.00 |
Depreciation &
Amortization |
$17.48 M
|
$16.32 M
|
$14.71 M
|
$15.04 M
|
$9.05 M
|
$7.08 M
|
$2.89 M
|
$2.37 M
|
$3.18 M
|
$1.29 M
|
EBITDA |
-$364.52 M
|
-$383.46 M
|
-$191.87 M
|
-$183.10 M
|
-$120.42 M
|
$59.42 M
|
-$57.01 M
|
-$5.48 M
|
-$31.55 M
|
-$20.37 M
|
EBITDA Ratio |
-5.8 |
-7.25 |
-4.8 |
-5.83 |
-5.68 |
0.39 |
-6.99 |
-1.19 |
-8.25 |
-44.26 |
Operating Income Ratio
|
-6.02
|
-6.96
|
-5.04
|
-6.21
|
-6.11
|
0.34
|
-7.35
|
-16.12
|
-9.08
|
-47.09
|
Total Other
Income/Expenses Net |
-$183.25 M
|
-$94.48 M
|
-$109.05 M
|
-$164.39 M
|
-$84.30 M
|
-$37.02 M
|
-$4.94 M
|
$60.25 M
|
-$1.62 M
|
-$243,579.00
|
Income Before Tax |
-$561.75 M |
-$462.53 M |
-$310.58 M |
-$359.58 M |
-$213.78 M |
$15.32 M |
-$64.83 M |
-$13.76 M |
-$36.36 M |
-$21.91 M |
Income Before Tax Ratio
|
-8.94
|
-8.74
|
-7.77
|
-11.44
|
-10.09
|
0.1
|
-7.95
|
-3
|
-9.51
|
-47.62
|
Income Tax Expense |
-$2.42 M |
-$33.52 M |
-$2.01 M |
-$473,000.00 |
-$6.27 M |
-$36.04 M |
-$896,000.00 |
$36.31 M |
-$1.70 M |
$9,615.00 |
Net Income |
-$559.33 M |
-$429.01 M |
-$308.57 M |
-$359.10 M |
-$203.54 M |
$9.06 M |
-$60.92 M |
-$45.81 M |
-$34.66 M |
-$21.91 M |
Net Income Ratio |
-8.9 |
-8.11 |
-7.72 |
-11.42 |
-9.6 |
0.06 |
-7.47 |
-9.98 |
-9.06 |
-47.62 |
EPS |
-1.33 |
-1.46 |
-1.34 |
-2.56 |
-1.92 |
0.13 |
-1.21 |
-1.24 |
-1.3 |
-1.46 |
EPS Diluted |
-1.33 |
-1.46 |
-1.34 |
-2.56 |
-1.92 |
0.13 |
-1.21 |
-1.24 |
-1.3 |
-1.46 |
Weighted Average Shares
Out |
$419.32 M
|
$294.77 M
|
$229.82 M
|
$140.51 M
|
$106.15 M
|
$69.74 M
|
$50.36 M
|
$36.91 M
|
$26.68 M
|
$15.05 M
|
Weighted Average Shares
Out Diluted |
$419.32 M
|
$294.77 M
|
$229.82 M
|
$140.51 M
|
$106.15 M
|
$70.38 M
|
$50.36 M
|
$36.91 M
|
$26.68 M
|
$15.05 M
|
Link |
|
|
|
|
|
|
|
|
|
|